New in MS Research: Interplay Between IFN-beta, B-cells and Monocytes

B-Cells and Antibody Production in MS

Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system (CNS). It causes scar tissue (plaques) in the brain’s white matter and spinal cord, from myelin loss (demyelination) and axon death. MS has classically been seen as a T-cell-mediated disease. But B cell-depleting therapies work so well that they reveal B-lymphocytes and antibody responses also play a key role in MS — even though the exact mechanisms are still unclear. About 90% of MS patients show raised levels of IgG made locally in the CNS, found in both MS plaques and cerebrospinal fluid (CSF). This is a sign of B-cell clonal expansion within the CNS.

B-cell-lineage cells turn into antibody-secreting plasma cells — the source of persistent IgG — with help from key factors:

• Interleukin-6 (IL-6), which drives B cells to fully differentiate into plasma cells and is essential for their survival and antibody secretion.
• B-cell-activating factor of the TNF family (BAFF) and a proliferation-inducing ligand (APRIL), which together regulate B-cell survival and differentiation, and are essential for starting T-cell-independent B-cell responses.

Type I Interferons and Toll-Like Receptors

Type I IFNs (IFN-α, IFN-β, IFN-κ, and IFN-ω) are cytokines made by many cell types in response to viral or microbial infection. They bind specific Toll-like receptors (TLRs), which switch on genes that link innate and adaptive immunity.

IFN-β is still the first-line disease-modifying drug for relapsing-remitting multiple sclerosis (RRMS), even with newer treatments now available. Understanding how IFN-β reduces inflammation in RRMS could shed light on MS more broadly.

TLRs are pattern-recognition receptors. They detect specific molecular patterns from pathogens, as well as signals of damage from the body’s own cells. Beyond their central role in innate immunity, TLRs also help activate adaptive immunity by triggering proinflammatory cytokines such as TNF-α, IL-1, IL-6, IL-12, and IFN.

Humans have 11 known TLRs. Several studies show that three of them — endosomal TLR7, TLR8, and TLR9, which normally detect pathogen-derived and synthetic nucleic acids — also detect self-nucleic acids in immune complexes in autoimmune diseases like MS. B-cells express both TLR7 and TLR9:

• TLR7 recognizes guanosine- and uridine-rich single-stranded RNAs (ssRNAs).
• TLR9 recognizes hypomethylated CpG-rich double-stranded DNA.

Once activated by these targets, TLR7 and TLR9 drive B cells to proliferate and turn into antibody-secreting cells.

IFN-β Therapy Restores B-Cell Signaling in MS Patients

In a study in the European Journal of Immunology, Coccia’s group showed that monocytes and B cells must interact for the body to mount an effective antibody response — specifically, for TLR7 to drive B cells into antibody-secreting cells. They also found this cross-talk was clearly weaker in MS patients: peripheral blood mononuclear cells (PBMCs) from MS patients produced much less TLR7-induced antibody than PBMCs from healthy donors.

After one month of IFN-β therapy, this weakened response bounced back. IFN-β did this by triggering secretion of cytokines that activate TLR7, raising IgM and IgG back to levels seen in healthy donors. This shows IFN-β boosts TLR7-driven B-cell responses in MS patients in at least two ways:

• By regulating TLR7 gene expression.
• By triggering secretion of B-cell differentiation factors — especially IL-6 and BAFF.

A Newly Identified Defect in Monocytes

Perhaps the biggest finding in Coccia’s study: this is the first report of a defect in TLR7 gene expression and signaling in the monocytes of MS patients. When researchers removed monocytes from IFN-β-treated MS patient PBMC samples, they saw:

• No TLR7-driven IgM and IgG production.
• No IL-6.
• A big drop in BAFF expression.

This shows IFN-β works therapeutically by fine-tuning monocyte function — activating TLR7, which then shapes B cell differentiation.

These findings show how tightly TLR expression and TLR-driven responses are regulated to keep the immune system balanced, and how IFN-β helps restore TLR7 function. Together, they point to important shifts in the PBMC environment driven by IFN-β therapy — shifts where different leukocyte subsets interact to shape the body’s immune tolerance.

What This Means for MS Treatment

Coccia’s new study gives fresh insight into MS immunopathology. It matters for developing new MS therapies that target TLR expression and TLR-induced responses.

Sanguine supplies research-grade human PBMCs for studies like this.

Further Reading

IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.